These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16420569)

  • 21. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
    Bowyer AE; Hillarp A; Ezban M; Persson P; Kitchen S
    J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Novel Assessment of Factor VIII Activity by Template Matching Utilizing Weighted Average Parameters from Comprehensive Clot Waveform Analysis.
    Shimonishi N; Ogiwara K; Oda Y; Kawabe T; Okazaki S; Shima M; Nogami K
    Thromb Haemost; 2021 Feb; 121(2):164-173. PubMed ID: 32828071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A micromethod for clotting tests and coagulation factor assays.
    Exner T; Margolis J; Rickard KA
    Clin Lab Haematol; 1980; 2(3):227-30. PubMed ID: 6775862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays.
    Radtke KP; Griffin JH; Riceberg J; Gale AJ
    J Thromb Haemost; 2007 Jan; 5(1):102-8. PubMed ID: 17059431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring of modified factor VIII and IX products.
    Kitchen S; Gray E; Mertens K
    Haemophilia; 2014 May; 20 Suppl 4():36-42. PubMed ID: 24762273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A hemophilia A mouse model for the in vivo assessment of emicizumab function.
    Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV
    Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
    Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
    Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.
    Waters EK; Genga RM; Schwartz MC; Nelson JA; Schaub RG; Olson KA; Kurz JC; McGinness KE
    Blood; 2011 May; 117(20):5514-22. PubMed ID: 21389323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bleeding risk in hemophilia A and B carriers: comparison of factor levels determined using chronometric and chromogenic assays.
    Chiffré-Rakotoarivony D; Diaz-Cau I; Ranc A; Champiat MA; Rousseau F; Gournay-Garcia C; Théron A; Navarro R; Boulot P; Aguilar-Martinez P; Sauguet P; Biron-Andréani C
    Blood Coagul Fibrinolysis; 2024 Jul; 35(5):232-237. PubMed ID: 38700721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
    Beckman JD; Holle LA; Wolberg AS
    J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A bispecific antibody demonstrates limited measurability in routine coagulation assays.
    Hartmann R; Feenstra T; Knappe S; Schrenk G; Scheiflinger F; Dockal M
    Blood Coagul Fibrinolysis; 2020 Sep; 31(6):353-365. PubMed ID: 32467424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
    Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
    Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report.
    Shirahata A; Fukutake K; Mimaya J; Takamatsu J; Shima M; Hanabusa H; Takedani H; Takashima Y; Matsushita T; Tawa A; Higasa S; Takata N; Sakai M; Kawakami K; Ohashi Y; Saito H
    Haemophilia; 2013 Mar; 19(2):330-7. PubMed ID: 22989180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Global hemostatic assay of different target procoagulant activities of factor VIII and factor IX.
    Yoo KY; Jung SY; Hwang SH; Lee SM; Park JH; Nam HJ
    Blood Res; 2018 Mar; 53(1):41-48. PubMed ID: 29662861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX.
    He S; Blombäck M; Jacobsson Ekman G; Hedner U
    J Thromb Haemost; 2003 Jun; 1(6):1215-9. PubMed ID: 12871322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A.
    Ninivaggi M; Dargaud Y; van Oerle R; de Laat B; Hemker HC; Lindhout T
    J Thromb Haemost; 2011 Aug; 9(8):1549-55. PubMed ID: 21605333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: A real-life study.
    Atsou S; Furlan F; Duchemin J; Ellouze S; Sourdeau É; Launois A; Roussel-Robert V; Stieltjes N; Combe S; Fontenay M; Curis E; Jourdi G
    Eur J Pharmacol; 2021 Jan; 891():173764. PubMed ID: 33249076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.
    Kitchen S; Blakemore J; Friedman KD; Hart DP; Ko RH; Perry D; Platton S; Tan-Castillo D; Young G; Luddington RJ
    J Thromb Haemost; 2016 Apr; 14(4):757-64. PubMed ID: 26748742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity.
    Matsumoto T; Nogami K; Shima M
    Int J Hematol; 2017 Feb; 105(2):174-183. PubMed ID: 27730530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B.
    Marlar RA; Strandberg K; Shima M; Adcock DM
    Eur J Haematol; 2020 Jan; 104(1):3-14. PubMed ID: 31606899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.